Copertina

Trained immunity: A link between risk factors and cardiovascular disease

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Mingqi Chen, Xuya Kang, Yan Zhang, Yahan Liu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	British Journal of Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Exploring the link between antihypertensive drugs targets and pancreatitis risk through Mendelian randomization
di: Zhiwei Du, et al.
Pubblicazione: (2025)

Non‐canonical PKG1 regulation in cardiovascular health and disease
di: Jie Su, et al.
Pubblicazione: (2025)

Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia
di: Paul Dalmas, et al.
Pubblicazione: (2025)

Impact of diclofenac risk minimization measures addressing cardiovascular risk on analgesic use in musculoskeletal disorders
di: Tomas Lasys, et al.
Pubblicazione: (2025)

Empty lipid nanoparticles (eLNPs) with adjuvant activity induce potent immune responses
di: De‐Kui Qiu, et al.
Pubblicazione: (2026)

R2R01: A long‐acting single‐chain peptide agonist of RXFP1 for renal and cardiovascular diseases
di: Bruno Poirier, et al.
Pubblicazione: (2024)

Clinical characteristics and risk factors for antituberculosis drug‐induced hypersensitivity
di: Quanxian Liu, et al.
Pubblicazione: (2024)

Initiation of lipid‐lowering therapy as primary prevention of cardiovascular disease in the elderly
di: José Manuel Vinuesa‐Hernando, et al.
Pubblicazione: (2024)

Short‐chain fatty acids regulate T cell heterogeneity to alleviate recurrent spontaneous abortion
di: Yao Yao, et al.
Pubblicazione: (2025)

Opioid receptors in cardiovascular function
di: Venkatesh Katari, et al.
Pubblicazione: (2025)

Statins as a risk factor for anaemia: Evidence from genetic and epidemiological data
di: Zhekang Liu, et al.
Pubblicazione: (2025)

Ibuprofen inhibits human sweet taste and glucose detection implicating an additional mechanism of metabolic disease risk reduction
di: Emily C. Hanselman, et al.
Pubblicazione: (2025)

V‐domain immunoglobulin suppressor of T‐cell activation and programmed death receptor 1 dual checkpoint blockade enhances antitumour immunity and survival in glioblastoma
di: Shasha Jin, et al.
Pubblicazione: (2024)

CKLF‐like MARVEL transmembrane domain‐containing superfamily 8 (CMTM8) promotes Notch signalling to maintain CD8 + T cell‐ and NK cell‐dependent tumour immune escape
di: Fanglin Li, et al.
Pubblicazione: (2026)

The efficacy of hydroxychloroquine in paediatric chronic immune thrombocytopenia: A retrospective cohort study
di: Jing Liu, et al.
Pubblicazione: (2025)

Silibinin, a commonly used therapeutic agent for non‐alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19
di: Yujie Bai, et al.
Pubblicazione: (2024)

Integrative immunomodulation in systemic autoimmune diseases: Mechanistic complementarity and therapeutic strategies of traditional Chinese and conventional medicine
di: Xiaomeng Zhang, et al.
Pubblicazione: (2026)

Cell‐based therapy for diabetic cardiovascular complications: Prospects and challenges
di: Jia‐Peng Li, et al.
Pubblicazione: (2024)

Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients
di: Binbin Lv, et al.
Pubblicazione: (2024)

Paediatric sepsis survivors are resistant to sepsis‐induced long‐term immune dysfunction
di: David F. Colón, et al.
Pubblicazione: (2024)

Baclofen modulates the immune response after spinal cord injury with locomotor benefits
di: Nídia de Sousa, et al.
Pubblicazione: (2025)

The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases
di: Jiuguo Lin, et al.
Pubblicazione: (2024)

Dihydro‐resveratrol ameliorates NLRP3 inflammasome‐mediated neuroinflammation via Bnip3‐dependent mitophagy in Alzheimer's disease
di: Guorong Tao, et al.
Pubblicazione: (2024)

Overcoming barriers to adherence through innovative injectable medications: A systematic review of therapeutic options for cardiovascular disease, reported adherence, and perspectives on their use
di: Beata Bajorek, et al.
Pubblicazione: (2025)

Reprogramming tumour‐associated macrophages in breast cancer via si‐FOXM1‐loaded lipid nanoparticles enhances immune checkpoint inhibitor efficacy
di: Yali Gao, et al.
Pubblicazione: (2026)

First‐in‐human assessment of safety and pharmacokinetics of EP9001A:an anti‐nerve growth factor antibody for chronic pain treatment
di: Yue Cheng, et al.
Pubblicazione: (2025)

Correction to “RTP801 is a critical factor in the neurodegeneration process of A53T a‐synuclein in a mouse model of Parkinson's disease under chronic restraint stress”
Pubblicazione: (2024)

Insight into the regulatory mechanism of β‐arrestin2 and its emerging role in diseases
di: Meng Qi, et al.
Pubblicazione: (2024)

Anti‐cathepsin D immunotherapy triggers both innate and adaptive anti‐tumour immunity in breast cancer
di: Timothée David, et al.
Pubblicazione: (2024)

Kynurenic acid as a promising therapeutic agent in renal fibrosis: dual modulation of fibrosis and immune crosstalk
di: Sona Sykorova, et al.
Pubblicazione: (2026)

AdipoRon promotes amyloid‐β clearance through enhancing autophagy via nuclear GAPDH‐induced sirtuin 1 activation in Alzheimer's disease
di: Fengjiao Sun, et al.
Pubblicazione: (2024)

Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
di: Feng Zhang, et al.
Pubblicazione: (2024)

Optimizing mycophenolic acid exposure for reduced relapse risk in paediatric nephrotic syndrome: An observational cohort study
di: Yiting Cai, et al.
Pubblicazione: (2025)

Predicting potassium trajectories for risk monitoring in outpatients with heart failure, diabetes mellitus or chronic kidney disease
di: Camilo Scherkl, et al.
Pubblicazione: (2025)

The impact of Foxp3 + regulatory T‐cells on CD8 + T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors
di: Mikhaël Attias, et al.
Pubblicazione: (2024)

Population pharmacokinetics of rotigotine extended‐release microspheres for intramuscular injection in patients with early‐stage Parkinson's disease
di: Hong Sun, et al.
Pubblicazione: (2024)

The PARP inhibitor rucaparib blocks SARS‐CoV‐2 virus binding to cells and the immune reaction in models of COVID‐19
di: Henrietta Papp, et al.
Pubblicazione: (2024)

Pharmacological treatment with a GABA(A) receptor modulator and a selective serotonin reuptake inhibitor as a mitigation strategy against aircraft noise‐induced cardiovascular and neuronal damage
di: Ivana Kuntić, et al.
Pubblicazione: (2026)

Monovalent mannose‐glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions
di: María Elena Angarita‐Planchez, et al.
Pubblicazione: (2025)

Resolution pharmacology and the treatment of infectious diseases
di: Vivian Vasconcelos Costa, et al.
Pubblicazione: (2024)